Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
164.25 USD
1.05%
Market Closed
Updated:
Apr 18, 2024
Abbvie Inc
Accounts Receivables
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Accounts Receivables Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$7.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
31%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Accounts Receivables
$631.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
33%
|
CAGR 10-Years
36%
|
See Also
What is Abbvie Inc's Accounts Receivables?
Accounts Receivables
11.2B
USD
11.2B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Accounts Receivables amounts to 11.2B USD.
What is Abbvie Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
11%
11%
Over the last year, the Accounts Receivables growth was -1%. The average annual Accounts Receivables growth rates for Abbvie Inc have been 8% over the past three years , 16% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
